Universität zu Köln

Cozzi-Lepri, A., Zangerle, R., Machala, L., Zilmer, K., Ristola, M., Pradier, C., Kirk, O., Sambatakou, H., Faetkenheuer, G., Yust, I., Schmid, P., Gottfredsson, M., Khromova, I., Jilich, D., Flisiak, R., Smidt, J., Rozentale, B., Radoi, R., Losso, M. H., Lundgren, J. D. and Mocroft, A. (2018). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Med., 19 (2). S. 102 - 118. HOBOKEN: WILEY. ISSN 1468-1293

Full text not available from this repository.

Abstract

ObjectivesThere are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. MethodsThe EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. ResultsThe RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95-1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37-2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84-1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90-1.61) and 0.83 (95% CI 0.70-0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47-1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65-1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53-1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76-1.72 for RALvs. CONC). ConclusionsWe found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cozzi-Lepri, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zangerle, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Machala, L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Zilmer, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ristola, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pradier, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kirk, O. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sambatakou, H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Yust, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmid, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gottfredsson, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Khromova, I. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jilich, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Flisiak, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Smidt, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rozentale, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Radoi, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Losso, M. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lundgren, J. D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mocroft, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-198279
DOI:	10.1111/hiv.12557
Journal or Publication Title:	HIV Med.
Volume:	19
Number:	2
Page Range:	S. 102 - 118
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1468-1293
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language HIV INTEGRASE INHIBITORS; OPTIMIZED BACKGROUND THERAPY; AIDS-DEFINING CANCERS; HIV-1-INFECTED PATIENTS; INFECTED INDIVIDUALS; EXPERIENCED PATIENTS; IMMUNODEFICIENCY; SAFETY; COHORT; MALIGNANCIES Multiple languages Infectious Diseases Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/19827